Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Sarcoma 142Osteosarcoma 26Liposarcoma 25Leiomyosarcoma 25Histiocytoma, Malignant Fibrous 19Hemangiosarcoma 18Sarcoma, Synovial 17Neurofibrosarcoma 17Fibrosarcoma 17Rhabdomyosarcoma 16Dendritic Cell Sarcoma, Interdigitating 16Sarcoma, Ewing 13Neuroectodermal Tumors, Primitive, Peripheral 11HIV Infections 11Sarcoma, Kaposi 10Neoplasms 10Neoplasm Metastasis 10Malignant mesenchymal tumor 10Acquired Immunodeficiency Syndrome 10Lymphoma, Large B-Cell, Diffuse 9Dermatofibrosarcoma 9Ovarian Neoplasms 8Lymphoma 8Hemangiopericytoma, Malignant 8Desmoplastic Small Round Cell Tumor 8Sarcoma, Alveolar Soft Part 6Chondrosarcoma, Extraskeletal Myxoid 6Bone Neoplasms 6Chondrosarcoma 5Burkitt Lymphoma 5

Interventions

liposomal doxorubicin 1Taxes 1Paclitaxel 1Lomustine 1Irinotecan 1Gemcitabine 1Doxorubicin 1Carboplatin 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × Doxorubicin × Sarcoma × Clear all
NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

Phase 2 Active not recruiting
350 enrolled
BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡